Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced Salivary Gland Cancer (Phase II)
2018-000682-36Phase 2Terminated
- Sponsor
- Radboud University Medical Center
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in salivary gland cancer (SGC), sponsored by Radboud University Medical Center. Primary endpoint: Overall response rate. Started May 2018; status: terminated.
02
Drugs
cabozantinib
03
Conditions
salivary gland cancer (SGC)
Beyond the preview
Go deeper on 2018-000682-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000682-36.